NCT01012765 - Effect of Indacaterol on Inspiratory Capacity (IC) | Biotech Hunter

Enrollment

173

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

January 31, 2011

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Indacaterol

Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)

DRUG

Tiotropium

Tiotropium 18µg o.d. delivered via a proprietary inhalation device.

DRUG

Placebo

Placebo to indacaterol o.d. delivered via SDDPI

Trial Locations (21)

Novartis Investigative Site, Aschaffenburg

Novartis Investigative Site, Berlin

Novartis Investigative Site, Dresden

Novartis Investigative Site, Erfurt

Novartis Investigative site, Frankfurt am Main

Novartis Investigative Site, Fulda

Novartis Investigative Site, Geesthacht

Novartis Investigative Site, Großhansdorf

Novartis Investigative Site, Halle

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Kiel

Novartis Investigative Site, Koblenz

Novartis Investigative site, Leipzig

Novartis Investigative Site, Mannheim

Novartis Investigative Site, Marburg

Novartis Investigative Site, Neumünster

Novartis Investigative Site, Potsdam

Novartis Investigative Site, Rathenow

Novartis Investigative Site, Rüdersdorf

Novartis Investigator Site, Witten

Novartis Investigative Site, Zerbst